🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Wells Fargo boosts HealthEquity shares target, cites strong position in expanding HSA market

EditorEmilio Ghigini
Published 07/05/2024, 11:26
HQY
-

On Tuesday, Wells Fargo (NYSE:WFC) maintained its Overweight rating on HealthEquity, Inc. (NASDAQ:HQY) and increased the shares target to $105.00 from the previous $93.00.

The firm's analyst highlighted the company's potential to benefit from the growing market for health savings accounts (HSAs). HealthEquity is expected to continue capturing over 30% of new HSA accounts and maintain at least a 20% market share.

The analyst projects that the HSA market, which currently consists of approximately 36 million accounts with $116 billion in assets under management (AUM), is set to expand to around 60 million accounts and over $300 billion in AUM within the next decade. This growth trajectory is seen as an opportunity for HealthEquity to further solidify its position in the industry.

HealthEquity's business model was also a point of interest for the analyst. The company operates with a light capital model, which is anticipated to yield approximately a 30% free cash flow (FCF) margin by the end of the decade. This financial framework is expected to support the company's continued growth and profitability.

The positive outlook on HealthEquity by Wells Fargo is based on the company's strong market presence and the anticipated growth of the HSA market. The revised price target reflects the firm's confidence in HealthEquity's ability to leverage its market position and capitalize on the expanding HSA space.

InvestingPro Insights

With Wells Fargo's recent endorsement of HealthEquity, Inc. (NASDAQ:HQY), investors may find additional context with InvestingPro data and tips insightful. The company's market capitalization currently stands at $6.83 billion, and it has been trading at a high P/E ratio of 121.69. This is noteworthy, as it indicates a significant expectation of future earnings growth, especially considering the adjusted P/E ratio for the last twelve months as of Q4 2024 is slightly lower at 107.49. HealthEquity's revenue growth has been robust, with a 16.0% increase over the last twelve months leading up to Q4 2024, suggesting a strong trajectory in line with analyst projections.

According to InvestingPro Tips, HealthEquity is expected to see net income growth this year, which could justify the high earnings multiple. Another tip points out that the stock generally trades with low price volatility, which might appeal to investors looking for stability in their portfolio. It's also worth noting that HealthEquity has liquid assets that exceed short-term obligations, indicating a solid liquidity position.

For investors who are considering a deeper dive into HealthEquity's financials and potential, there are 14 additional InvestingPro Tips available at https://www.investing.com/pro/HQY. These tips provide a comprehensive analysis that could be crucial for making informed investment decisions. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking further insights into HealthEquity's market performance and future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.